Endometrial Cancer | Topics

PD-1 Inhibitor Dostarlimab Earns Accelerated Approval in Mismatch Repair Deficient Endometrial Cancer
April 22, 2021

Based on results from the phase 2 GARNET trial, dostarlimab may be used to treat recurrent or advanced endometrial cancer progressing on or after treatment with a platinum-containing chemotherapy that is mismatch repair deficient.

Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer
March 25, 2021

The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.

Addition of Olaparib to Cediranib Does Not Induce Superior Efficacy in Advanced Endometrial Cancer
March 22, 2021

The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.